Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
56.06
-0.97 (-1.70%)
Nov 22, 2024, 4:00 PM EST - Market closed
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for CRNX stock have an average target of 73.7, with a low estimate of 54 and a high estimate of 97. The average target predicts an increase of 31.47% from the current stock price of 56.06.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CRNX stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 9 | 9 | 9 | 8 | 8 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $70 → $74 | Strong Buy | Maintains | $70 → $74 | +32.00% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $69 → $81 | Strong Buy | Maintains | $69 → $81 | +44.49% | Nov 13, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $80 | Buy | Reiterates | $80 | +42.70% | Sep 27, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $90 | Buy | Reiterates | $90 | +60.54% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $69 | Strong Buy | Maintains | $60 → $69 | +23.08% | Aug 9, 2024 |
Financial Forecast
Revenue This Year
2.03M
from 4.01M
Decreased by -49.31%
Revenue Next Year
12.09M
from 2.03M
Increased by 494.25%
EPS This Year
-3.77
from -3.69
EPS Next Year
-3.94
from -3.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.3M | 59.9M | 128.5M | ||
| Avg | 2.0M | 12.1M | 52.4M | ||
| Low | 980,000 | 2.9M | 24.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 57.0% | 2,842.5% | 962.9% | ||
| Avg | -49.3% | 494.2% | 333.7% | ||
| Low | -75.6% | 44.5% | 103.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.51 | -2.99 | -2.31 | ||
| Avg | -3.77 | -3.94 | -3.91 | ||
| Low | -3.83 | -4.42 | -4.50 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.